News about Clinical Trials

Sobi Reports Positive Phase 3 Results for Pozdeutinurad in Gout

Sobi reports positive Phase 3 REDUCE-2 results for investigational gout treatment pozdeutinurad, demonstrating sustained serum urate reduction over 12 months.

Clinical Trials | 30/10/2026 | By News Bureau

Vanda Pharma's NEREUS Shows Positive Results in GLP-1 Vomiting Study

Vanda Pharmaceuticals has reported positive NEREUS Study 3601 results, showing reduced semaglutide-induced vomiting, including frequent, multi-day and extreme episodes.

Clinical Trials | 30/10/2026 | By News Bureau

Eli Lilly Reports Phase 3 Results for Retatrutide Against Ozempic in Type 2 Diabetes

Eli Lilly has reported positive Phase 3 results for investigational retatrutide, which demonstrated greater reductions in A1C and body weight than Ozempic 2 mg in adults with type 2 diabetes. Retatrutide is not approved for human use.

Clinical Trials | 29/10/2026 | By News Bureau

Pfizer's ELREXFIO Meets Phase 3 Endpoint in Myeloma

Pfizer’s ELREXFIO has outperformed standard regimens and meets primary endpoint in phase 3 study in Relapsed or Refractory Multiple Myeloma (RRMM).

Clinical Trials | 28/10/2026 | By News Bureau

Roche's Sefaxersen Cuts Proteinuria in Phase 3 IgAN Trial

Roche has announced new phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN).

Clinical Trials | 27/10/2026 | By News Bureau

AstraZeneca's Sonesitatug Vedotin Cuts Death Risk by 42 Percent

AstraZeneca’s sonesitatug vedotin cuts death risk by 42 percent in advanced CLDN18.2-positive gastric cancer, with a 53 percent reduction in later-line treatment.

Clinical Trials | 26/10/2026 | By News Bureau

Teva and Sanofi Report Long-Term Data for Duvakitug

Teva and Sanofi have reported positive phase 2b data for duvakitug, showing sustained clinical remission and response in Ulcerative Colitis and Crohn’s Disease.

Clinical Trials | 23/10/2026 | By News Bureau |  280

ENTYVIO Trial Shows Disease Clearance Benefits in Ulcerative Colitis

The first Ulcerative Colitis treat-to-target trial shows ENTYVIO (vedolizumab) delays disease-related complications with disease clearance versus symptomatic remission.

Clinical Trials | 22/10/2026 | By News Bureau |  215

GSK Reveals First Global Ris-Rez Data in Small Cell Lung Cancer

GSK has reported first global Ris-Rez data in ES-SCLC, with a 61 percent response rate in a phase 1b trial supporting further clinical development.

Clinical Trials | 22/10/2026 | By News Bureau

Tiziana Doses Last Patient in Phase 2 Trial of Foralumab

Tiziana has dosed the last patient in its phase 2 trial of intranasal foralumab for mild Alzheimer’s, evaluating monotherapy and combinations with lecanemab or donanemab.

Clinical Trials | 19/10/2026 | By News Bureau